NasdaqGS:ARWRBiotechs
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following First Dual-Gene RNAi Cardio Trial Initiation
Arrowhead Pharmaceuticals recently dosed the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi therapeutic targeting atherosclerotic cardiovascular disease caused by mixed hyperlipidemia by silencing PCSK9 and APOC3.
This is the first clinical RNAi candidate designed to simultaneously target two genes in a single molecule, highlighting a new approach to treating residual cardiovascular risk in patients with elevated LDL cholesterol and triglycerides.
We will now explore how this...